SEC Company Response from Adaptive Biotechnologies Corp (ADPT) (CIK 0001478320) (ADPT) — Jan 21, 2020
Adaptive Biotechnologies Corp (ADPT) (CIK 0001478320)
Date: Jan. 21, 2020 · CIK: 0001478320 · Accession: 0001193125-20-011136
AI Filing Summary & Sentiment
File numbers found in text: 333-235989
Letter
Re: Adaptive Biotechnologies Corporation
January 21, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tim Buchmiller
Registration Statement on Form S-1
File No. 333-235989
Acceleration Request
Requested Date: January 23, 2020
Requested Time: 4:30 p.m., Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 460 under the Securities Act of 1933, as amended (the “Securities Act”), we, the representatives of the underwriters (the “Representatives”), wish to advise you that as of the time of this filing, the underwriters have not yet made any distribution of the Preliminary Prospectus of Adaptive Biotechnologies Corporation, a Washington corporation (the “Registrant”), dated January 21, 2020. However, the underwriters are taking steps to see that all underwriters, brokers or dealers participating in the public offering of shares of the Registrant’s common stock pursuant to the above-captioned Registration Statement, are promptly furnished with sufficient copies of the preliminary and final prospectus to enable them to comply with the prospectus delivery requirements of Section 5(b)(1) and (2) of the Securities Act.
We, the undersigned Representatives, have and will, and we have been informed by the participating underwriters that they have and will, comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, in connection with the proposed offering.
In accordance with Rule 461 of the Securities Act, we hereby join in the request of the Registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:30 p.m. Eastern Time on January 23, 2020, or as soon thereafter as practicable. We, the undersigned Representatives, confirm that the underwriters are aware of their obligations under the Securities Act.
[Signature Page Follows]
Very truly yours,
J.P. MORGAN SECURITIES LLC
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
January 21, 2020
VIA EDGAR
U.S. Securities and Exchange
Commission
Division of Corporation Finance
100 F Street,
N.E.
Washington, D.C. 20549
Attention:
Tim Buchmiller
Re:
Adaptive Biotechnologies Corporation
Registration Statement on Form S-1
File No. 333-235989
Acceleration Request
Requested Date: January 23, 2020
Requested Time: 4:30 p.m., Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 460 under the Securities
Act of 1933, as amended (the “Securities Act”), we, the representatives of the underwriters (the “Representatives”), wish to advise you that as of the time of this filing, the underwriters have not yet
made any distribution of the Preliminary Prospectus of Adaptive Biotechnologies Corporation, a Washington corporation (the “Registrant”), dated January 21, 2020. However, the underwriters are taking steps to see that all
underwriters, brokers or dealers participating in the public offering of shares of the Registrant’s common stock pursuant to the above-captioned Registration Statement, are promptly furnished with sufficient copies of the preliminary and final
prospectus to enable them to comply with the prospectus delivery requirements of Section 5(b)(1) and (2) of the Securities Act.
We, the
undersigned Representatives, have and will, and we have been informed by the participating underwriters that they have and will, comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of
1934, as amended, in connection with the proposed offering.
In accordance with Rule 461 of the Securities Act, we hereby join in the request of the
Registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:30 p.m. Eastern Time on January 23, 2020, or as soon thereafter as practicable. We, the undersigned Representatives, confirm that the
underwriters are aware of their obligations under the Securities Act.
[Signature Page Follows]
Very truly yours,
J.P. MORGAN SECURITIES LLC
GOLDMAN
SACHS & CO. LLC
BOFA SECURITIES, INC.
As representatives of the several underwriters listed in Schedule II to the Underwriting Agreement
J.P. MORGAN SECURITIES LLC
By:
/s/ Benjamin Burdett
Name: Benjamin Burdett
Title: Managing Director
GOLDMAN SACHS & CO. LLC
By:
/s/ Lyla Bibi Maduri
Name: Lyla Bibi Maduri
Title: Managing Director
BOFA SECURITIES, INC.
By:
/s/ Adam Chazan
Name: Adam Chazan
Title: Managing Director
cc:
Chad Robins, Chief
Executive Officer
Chad Cohen, Chief Financial Officer
Stacy
Taylor, General Counsel
Adaptive Biotechnologies Corporation
James Evans, Esq.
Amanda Rose, Esq.
Jennifer Hitchcock, Esq.
Fenwick & West LLP
Andrew
Ledbetter, Esq.
Tyler Hollenbeck, Esq.
DLA Piper LLP
(US)
[Signature Page to Underwriter Acceleration Request]